Non–Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves | Circulation
Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing | Published in Journal of Health Economics and Outcomes Research
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease | Journal of the American College of Cardiology
Risk and benefit of Anticoagulants in NVAF
Four main groups of patients with AF requiring long-term... | Download Scientific Diagram
Guideline of atrial fibrillation management
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model | Arteriosclerosis, Thrombosis, and Vascular Biology
Présentation PowerPoint
Non–Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves | Circulation
Heart valve disease module 7: anti-thrombotic therapy for valvular heart disease - The British Journal of Cardiology
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although. - ppt download
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study | Drugs in R&D
PDF) Non–Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs) - ScienceDirect
Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
Valvular vs Non-Valvular Atrial Fibrillation - Classification Valvular: ... | GrepMed
Home - ICHP KeePosted
Antithrombotic Therapy in Patients With Valvular Heart Disease
Bioprosthetic Valve Thrombosis | Journal of the American College of Cardiology
Anticoagulant Options in Patients with AF & Valvular Heart Disease
Surgery | Thrombosis Adviser
RCTs comparing a NOAC vs. warfarin in patients with mechanical... | Download Scientific Diagram
Role of oral anticoagulant (OAC) in Valvular AF patients
